Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for relapsed and refractory inflammatory myopathy
ChiCTR2300070348Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in Autoimmune Myopathies comparing Telitacicept arm with Placebo arm (2 arms). Primary endpoint: International Myositis Assessment and Clinical Studies definition of improvement (IMACS). Planned start Nov 2022; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on ChiCTR2300070348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070348.